ALDH18A1 and breast cancer: The role of P5CS is likely to be context-specific, as, in breast cancer, CRISPR/Cas9-mediated knockout of P5CS had no impact on tumor growth, but it sensitized cancer cells to pharmacological inhibition of lipogenesis, indicating that inhibition of proline biosynthesis could synergize with therapies targeting lipid metabolism122.